Skip to main content

Value Stock - Dividend - Research Selection

ISIN: , WKN:

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield%
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Farmer Bros. Co. Announces Board Refresh and Cooperation Agreement with Stockholders JCP Investment Management and 22NW

2022-10-31
NORTHLAKE, Texas, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Farmer Bros. Co. (NASDAQ: FARM) (the “Company”), today announced it has entered into a cooperation agreement (the “Cooperation Agreement”) with JCP Investment Management, LLC (collectively with its affiliates, “JCP”) and 22NW, LP (collectively with its affiliates, “22NW”), which together own approximately 15.7% of the Company’s outstanding common stock. Under the Cooperation Agreement, the Company has agreed to promptly appoint Bradley L. Radof

Enzo Biochem, Inc. Appoints Patricia Eckert, CPA as Interim CFO

2022-10-20
- David Bench resigning to pursue a new career opportunity -NEW YORK, NY, Oct. 20, 2022 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”), a leading biosciences and diagnostics company, today announced the appointment of Patricia Eckert, CPA, as interim Chief Financial Officer (CFO). Ms. Eckert’s appointment follows the resignation of David Bench, who is departing the Company effective November 14, 2022 to pursue a new opportunity. “While bittersweet in light of David’

Enzo Biochem appoints Eckert as interim CFO

2022-10-20
Enzo Biochem announced th... ENZ

The past five years for Enzo Biochem (NYSE:ENZ) investors has not been profitable

2022-10-17
Long term investing works well, but it doesn't always work for each individual stock. We don't wish catastrophic...

Enzo Biochem Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Business Update

2022-10-14
- Enzo Life Sciences reports revenue of $32.6 million and 8% growth in FY 2022, net of FX - Company successfully launched AMPIVIEW™ gene expression platform powered by LoopRNA™ ISH technology - Continues to engage with previously announced investment bank to provide advisory services including the evaluation of strategic alternatives for the Company - Under the leadership of a new CEO, Enzo has been reorganized to leverage on our ‘focused return’ strategy including the appointment of new executi

Enzo Biochem: Fiscal Q4 Earnings Snapshot

2022-10-14
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Enzo Biochem reports Q4 EPS (17c) vs. 7c last year

2022-10-14
Reports Q4 revenue $20.3M... ENZ

Enzo Biochem to Report Fourth Quarter 2022 Financial Results and Business Update on Friday, October 14th

2022-10-10
Conference Call and Webcast Scheduled for October 14, 2022, 8:30 am ET NEW YORK, NY, Oct. 10, 2022 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ), a leading biosciences and diagnostics company, announced today that it will report fourth quarter 2022 financial results on Friday, October 14, 2022, premarket. The announcement will be followed by a live audio webcast and conference call the same day at 8:30 am Eastern Time. Please see additional details below: Friday, October 14th @ 8:30 am ETDom

Enzo Biochem, Inc. Opens Expanded Life Sciences Laboratory and Office Facilities in Farmingdale, New York

2022-10-06
100,000 square foot facility to support company plans for growth in clinical laboratory services, drug development services and product innovations Launch event to feature updates on Enzo plans for business growth and perspectives on prospects for the Long Island business community from community leaders including Senator John Brooks and Assemblyman Steve Stern New York, NY, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”), a leading biosciences and diag

Enzo Biochem opens life sciences lab, office facilities in Farmingdale, NY

2022-10-06
Enzo Biochem announced th... ENZ